Humanized NaV1.8 Rats Tackle Cross-Species Differences in the Quest for Non-Opioid Pain Relief
On February 12, 2026, Vertex Pharmaceuticals released its Full Year 2025 Financial Results, unveiling a commercial trajectory for JOURNAVX (suzetrigine) that has not only met but in several key areas exceeded the high expectations of the pharmaceutical industry. The data is nothing short of eye-catching: since its March debut, the first-in-class NaV1.8 inhibitor has seen more than 550,000 prescriptions filled, with quarterly revenues skyrocketing from a modest $1M in Q1 to a staggering $27M by Q4, totaling $60M for the fiscal year. This momentum is matched by a massive structural shift in market access, as the drug secured coverage for 200 million American lives—representing two-thirds of all covered individuals in the U.S.—and successfully integrated into the formularies of nearly 1,000 targeted hospitals [1]. Such exponential revenue growth and rapid absorption into national healthcare protocols signal a definitive future where selective NaV1.8 inhibitors become the gold standard, effectively stripping opioids of their clinical dominance and fundamentally rewriting the landscape of pain management.
The New Era of Non-Opioid Analgesia: Clinical and Legislative Progress
The global pain management landscape is currently defined by a critical tension between the universal need for effective relief and the devastating public health crisis fueled by opioid addiction. While opioids offer potent analgesia, their high potential for abuse and fatal respiratory depression has necessitated a fundamental shift toward non-addictive alternatives. A historic milestone in this transition occurred on January 30, 2025, with the FDA approval of Journavx (Suzetrigine), the first oral, selective NaV1.8 sodium channel inhibitor for moderate-to-severe acute pain [2]. As the first major breakthrough in non-opioid analgesics in over two decades, Suzetrigine represents a pivotal move toward "addiction-free" pain control, even as its current indications remain limited to acute cases.
To address the vast unmet need in chronic pain, Vertex is aggressively expanding its clinical focus toward Diabetic Peripheral Neuropathy (DPN), aiming to complete Phase 3 enrollment by late 2026 as a bridge to broader markets like Small Fiber Neuropathy (SFN). The commercial potential of this new drug class has triggered intense industry competition, notably Eli Lilly’s $1 billion acquisition of SiteOne Therapeutics to secure the NaV1.8 inhibitor STC-004 [3].
Parallel to these pharmaceutical advancements, the U.S. government strengthened its systemic response to the epidemic when the bipartisan SUPPORT for Patients and Communities (SUPPORT) Reauthorization Act of 2025 (H.R. 2483) was signed into law on December 1 [4]. By restoring vital federal funding through 2030 for prevention, treatment, and recovery services, this bipartisan law ensures a sustained public health framework that complements the broader global push for safer, non-opioid pain management options.
NaV1.8: An Ideal Target for Novel Analgesic Drugs
This legislative momentum for non-addictive treatments underscores the clinical urgency of targeting the biological foundations of pain, specifically voltage-gated sodium channels (NaV). These channels serve as the primary gatekeepers for pain signal transmission within the nervous system. By regulating stimulus conduction, action potential firing, and neurotransmitter release across peripheral sensory neurons, the NaV family directly dictates how pain is perceived by the brain [6]. While various anti-epileptic and anti-arrhythmic drugs already utilize these channels, the current shift toward a post-opioid landscape has repositioned NaV channels—and NaV1.8 in particular—as the premier targets for the next generation of precision analgesics.
Comparing NaV1.7 and NaV1.8 as Therapeutic Targets: Why NaV1.8 Wins in Clinical Development
Within the NaV family, NaV1.7 and NaV1.8 are the primary focuses of analgesic research. However, the development of NaV1.7 inhibitors has repeatedly faced setbacks in clinical trials due to several significant hurdles. Researchers have encountered insufficient spinal inhibition and a short duration of action, alongside off-target side effects such as anosmia and various toxicity issues [7-8]. These failures suggest a discrepancy between pharmacological blockade and genetic deletion of NaV1.7, and they point toward potential compensatory mechanisms in pain signaling that allow the body to bypass the blocked channel. In contrast, NaV1.8 offers unique advantages because it is highly selectively expressed in peripheral pain-sensing neurons. It plays a key role in the sustained propagation of action potentials, allowing for more effective blocking of pain signals [9].
Recent research by Vertex Pharmaceuticals indicates that NaV1.8 expression was not detected in the central nervous system (CNS) across various samples in multiple databases. This implies that highly selective NaV1.8 inhibitors can:
- Specifically reduce pain signal transmission in peripheral sensory nerves.
- Avoid CNS side effects common to non-selective NaV blockers.
- Eliminate risks of tolerance and addiction associated with opioids [10-11].
By selectively blocking the influx of sodium ions, NaV1.8 inhibitors reduce the excitability of sensory neurons, acting on pain signals before they ever reach the central nervous system. This peripheral selectivity is its core clinical advantage.
Figure 4. Suzetrigine produces tonic inhibition by stabilizing the closed state of NaV1.8 [11].
While the therapeutic potential of NaV1.8 is clear, the path to clinical success depends entirely on the predictive power of preclinical models. Traditionally, rats have been the "gold standard" for pain research, offering physiological and pharmacological profiles that more closely resemble humans than smaller rodents. Their diverse behavioral phenotypes also allow for a more nuanced assessment of pain relief than is possible in mouse models [12-13].
However, the transition from "bench to bedside" is often obstructed by interspecies structural differences within the NaV1.8 channel itself. These subtle molecular variations can lead to significant discrepancies in drug efficacy, a challenge recently highlighted by researchers at Merck & Co., Inc. During the development of their NaV1.8 inhibitor pipeline, Merck discovered that while several candidates showed exceptional potency and selectivity against human channels in vitro, they exhibited a "marked rightward shift" (a decrease in potency) when tested against native rodent channels. This lack of cross-species conservation severely hindered the ability to screen and select viable candidates using traditional in vivo models [15].
To overcome this bottleneck, the development of humanized rat models has become critical. By utilizing genomic engineering to replace endogenous rat sequences with their human counterparts, researchers create a high-fidelity environment where human-specific inhibitors can be evaluated accurately [14]. As demonstrated by Merck’s specialized humanized NaV1.8 rat, these models simulate human responses with far greater precision, providing a reliable platform that accelerates the R&D process and ensures that promising analgesics do not fail simply due to a "lost in translation" effect [15].
Cyagen SD-hSCN10A(NaV1.8) Humanized Rat:A Validated Model for NaV1.8 Inhibitor Drug Discovery
Cyagen SD-hSCN10A(NaV1.8) Humanized Rat:A Validated Model for NaV1.8 Inhibitor Drug Discovery
When paired with various pain induction methods, such as thermal, mechanical, and chemical stimuli, or models for inflammation and nerve injury, this rat provides a highly accurate and human-relevant platform. It allows researchers to screen, develop, and evaluate the pharmacological efficacy of new NaV1.8 inhibitors with much higher precision, ultimately streamlining the drug discovery pipeline and improving the likelihood of clinical success.
To ensure the highest level of reliability for drug discovery, we have completed rigorous validation of this model, proving it is a robust and effective platform for evaluating human-specific therapies. The following data demonstrates the model's high sensitivity and translational accuracy in a neuropathic pain setting.
References
[1] Vertex Pharmaceuticals. Fourth Quarter and Full Year 2025 Financial Results [Presentation]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2026 Feb 12 [cited 2026 Feb 24]. Available from: https://investors.vrtx.com/static-files/6759ed5a-3de5-4ea9-81b2-ba99abfb333f
[2] Vertex Pharmaceuticals. Vertex announces FDA approval of JOURNAVX™ (suzetrigine), a first-in-class, oral, selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain [Internet]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2025 Jan 23 [cited 2026 Feb 24]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class
[3] Eli Lilly and Company. Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics [Internet]. Indianapolis (IN): Eli Lilly and Company; 2025 May 27 [cited 2026 Feb 24]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-expand-its-pain-pipeline-acquisition-siteone-therapeutics
[4] SUPPORT for Patients and Communities Reauthorization Act of 2025, H.R. 2483, 119th Cong. (2025). [Internet]. Washington (DC): Congress.gov; 2025 Dec 1 [cited 2026 Feb 25]. Available from: https://www.congress.gov/bill/119th-congress/house-bill/2483
[5] The White House. Bills Signed: H.R. 695 and H.R. 2483 [Internet]. Washington (DC): The White House; 2025 Dec 1 [cited 2026 Feb 25]. Available from: https://www.whitehouse.gov/briefings-statements/2025/12/congressional-bills-h-r-695-and-h-r-2483-signed-into-law/
[6] Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021 May;22(5):263-274.
[7] Chen R, Liu Y, Qian L, Yi M, Yin H, Wang S, Xiang B. Sodium channels as a new target for pain treatment. Front Pharmacol. 2025 Mar 26;16:1573254.
[8] Hang Kong AY, Tan HS, Habib AS. VX-548 in the treatment of acute pain. Pain Manag. 2024 Sep;14(9):477-486.
[9] Neumann B, McCarthy S, Gonen S. Structural basis of inhibition of human NaV1.8 by the tarantula venom peptide Protoxin-I. Nat Commun. 2025 Feb 7;16(1):1459.
[10] Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405.
[11] Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, Aertgeerts K, Negulescu PA, Lechner SM. Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain Ther. 2025 Apr;14(2):655-674.
[12] Larson CM, Wilcox GL, Fairbanks CA. The Study of Pain in Rats and Mice. Comp Med. 2019 Dec 1;69(6):555-570.
[13] Sadler KE, Mogil JS, Stucky CL. Innovations and advances in modelling and measuring pain in animals. Nat Rev Neurosci. 2022 Feb;23(2):70-85.
[14] Wang H, Huang J, Zang J, Jin X, Yan N. Drug discovery targeting Nav1.8: Structural insights and therapeutic potential. Curr Opin Chem Biol. 2024 Dec;83:102538.
[15] McDevitt DS, Vardigan JD, Zhou X, Rosahl TW, Zhou H, Price EA, Clements MK, Li Y, Varghese N, Krasowska-Zoladek A, Stachel SJ, Breslin MJ, Burgey CS, Kraus RL, Pall PS, Henze DA, Santarelli VP. Humanized NaV1.8 rats overcome cross-species potency shifts in developing novel NaV1.8 inhibitors. Neurobiol Pain. 2025 Mar 6;18:100182.
